Would you consider adjuvant capecitabine as well as trastuzumab in a patient with ER/PR negative, HER2 positive breast cancer treated with neoadjuvant chemotherapy /trastuzumab/pertuzumab who has residual disease on path?

The CREATE-X trial did not include HER-2 positive patients but the ER-negative population benefited from capecitabine. Would you consider capecitabine + a HER-2 agent in this setting? With the new data from the KATHERINE trial, would you substitute ado-trastuzumab?